Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An undifferentiated itch in a girl aged 14 years.

Australian journal of general practice·2026

Same author

Health-related quality of life in recessive dystrophic epidermolysis bullosa: findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES).

Orphanet journal of rare diseases·2026

Same author

Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.

Frontiers in oncology·2026

Same author

Bibliometrics-guided cyberpharmacology and transcriptomics for multidimensional analysis of the antihepatic fibrosis mechanism of kaempferol.

Frontiers in molecular biosciences·2025

Same author

Unveiling the therapeutic mechanisms of Saorilao-4 decoction in pulmonary fibrosis through metabolomics and transcriptomics.

Frontiers in nutrition·2025

Same author

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.

JNCI cancer spectrum·2025

Search research articles

Related Experiment Video

Updated: May 13, 2026

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Predicting OncoDx recurrence scores with immunohistochemical markers.

Scott H Bradshaw¹, Dale Pidutti, Denis H Gravel

¹*Department of Anatomic Pathology and Laboratory Medicine, Critical Care Wing, The Ottawa Hospital-General Campus †Department of Biology, Carleton University, Ottawa, ON, Canada.

Applied Immunohistochemistry & Molecular Morphology : AIMM

|March 5, 2013

Summary

A new immunohistochemistry risk score (IHC-RS) accurately predicts the OncoDx recurrence score (Onco-RS) in breast cancer patients. This simple IHC test offers similar prognostic value, potentially improving breast cancer recurrence prediction.

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: May 13, 2026

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Biomarkers
Genomics

Background:

Immunohistochemistry (IHC) markers show promise for prognostic information in breast cancer, comparable to genomic recurrence scores.
The OncoDx recurrence score (Onco-RS) is a validated tool for predicting breast cancer recurrence risk.

Purpose of the Study:

To evaluate the prognostic value of a novel IHC-based risk score (IHC-RS) in predicting the Onco-RS.
To determine if a simplified IHC panel can replicate the prognostic information of a complex genomic assay.

Main Methods:

A retrospective cohort of 158 women with ER-positive, HER2neu-negative breast cancer was analyzed.
An IHC-RS was developed using stepwise multiple regression with Ki67 percentage and semiquantitative ER/PR scores.
The IHC-RS was correlated with the Onco-RS to assess predictive accuracy.

Main Results:

The developed IHC-RS explained 62% of the variability in the Onco-RS (adjusted R=0.624, P=0.004).
Analysis of outliers suggested potential sampling error limitations within the Onco-RS.
Potential inter- and intra-laboratory variability and preanalytic issues were noted as challenges for IHC-RS implementation.

Conclusions:

A simple IHC-based risk score (IHC-RS) can effectively predict the OncoDx recurrence score (Onco-RS) in specific breast cancer subtypes.
This IHC-RS offers a potentially more accessible and cost-effective alternative for prognostic assessment in breast cancer.
Further research is needed to address variability issues for widespread clinical adoption of IHC-based risk scores.